Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Focal dose escalation for prostate cancer using 68Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference.
Zamboglou C, Thomann B, Koubar K, Bronsert P, Krauss T, Rischke HC, Sachpazidis I, Drendel V, Salman N, Reichel K, Jilg CA, Werner M, Meyer PT, Bock M, Baltas D, Grosu AL. Zamboglou C, et al. Among authors: bock m. Radiat Oncol. 2018 May 2;13(1):81. doi: 10.1186/s13014-018-1036-8. Radiat Oncol. 2018. PMID: 29716617 Free PMC article.
MRI versus ⁶⁸Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer.
Zamboglou C, Wieser G, Hennies S, Rempel I, Kirste S, Soschynski M, Rischke HC, Fechter T, Jilg CA, Langer M, Meyer PT, Bock M, Grosu AL. Zamboglou C, et al. Among authors: bock m. Eur J Nucl Med Mol Imaging. 2016 May;43(5):889-897. doi: 10.1007/s00259-015-3257-5. Epub 2015 Nov 23. Eur J Nucl Med Mol Imaging. 2016. PMID: 26592938
Comparison of 68Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology.
Zamboglou C, Drendel V, Jilg CA, Rischke HC, Beck TI, Schultze-Seemann W, Krauss T, Mix M, Schiller F, Wetterauer U, Werner M, Langer M, Bock M, Meyer PT, Grosu AL. Zamboglou C, et al. Among authors: bock m. Theranostics. 2017 Jan 1;7(1):228-237. doi: 10.7150/thno.16638. eCollection 2017. Theranostics. 2017. PMID: 28042330 Free PMC article.
The dose distribution in dominant intraprostatic tumour lesions defined by multiparametric MRI and PSMA PET/CT correlates with the outcome in patients treated with primary radiation therapy for prostate cancer.
Zamboglou C, Klein CM, Thomann B, Fassbender TF, Rischke HC, Kirste S, Henne K, Volegova-Neher N, Bock M, Langer M, Meyer PT, Baltas D, Grosu AL. Zamboglou C, et al. Among authors: bock m. Radiat Oncol. 2018 Apr 12;13(1):65. doi: 10.1186/s13014-018-1014-1. Radiat Oncol. 2018. PMID: 29650029 Free PMC article.
Correction to: Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET.
Wiedenmann N, Bunea H, Rischke HC, Bunea A, Majerus L, Bielak L, Protopopov A, Ludwig U, Büchert M, Stoykow C, Nicolay NH, Weber WA, Mix M, Meyer PT, Hennig J, Bock M, Grosu AL. Wiedenmann N, et al. Among authors: bock m. Radiat Oncol. 2018 Sep 21;13(1):183. doi: 10.1186/s13014-018-1134-7. Radiat Oncol. 2018. PMID: 30241555 Free PMC article.
[68Ga-]PSMA-11 PET/CT and multiparametric MRI for gross tumor volume delineation in a slice by slice analysis with whole mount histopathology as a reference standard - Implications for focal radiotherapy planning in primary prostate cancer.
Bettermann AS, Zamboglou C, Kiefer S, Jilg CA, Spohn S, Kranz-Rudolph J, Fassbender TF, Bronsert P, Nicolay NH, Gratzke C, Bock M, Ruf J, Benndorf M, Grosu AL. Bettermann AS, et al. Among authors: bock m. Radiother Oncol. 2019 Dec;141:214-219. doi: 10.1016/j.radonc.2019.07.005. Epub 2019 Aug 17. Radiother Oncol. 2019. PMID: 31431366
1,122 results